Symptoms, Side Effects and Adherence in the iPrEx Open-Label Extension.

PubWeight™: 0.76‹?›

🔗 View Article (PMID 26797207)

Published in Clin Infect Dis on January 20, 2016


David V Glidden1, K Rivet Amico2, Albert Y Liu3, Sybil G Hosek4, Peter L Anderson5, Susan P Buchbinder3, Vanessa McMahan6, Kenneth H Mayer7, Burns David8, Mauro Schechter9, Beatriz Grinsztejn10, Juan Guanira11, Robert M Grant12

Author Affiliations

1: University of California, San Francisco.
2: University of Michigan, Ann Arbor.
3: Bridge HIV, San Francisco Department of Public Health, California.
4: John Stroger Hospital of Cook County, Chicago, Illinois.
5: University of Colorado, Denver, Aurora.
6: University of Washington, Seattle.
7: Fenway Health and Beth Israel Deaconess Medical Center, Boston, Massachusetts.
8: National Institute of Allergy and Infectious Diseases, Rockville, Maryland.
9: Projeto Praça Onze, Hospital Escola São Francisco de Assis and Universidade Federal do Rio de Janeiro, and.
10: Evandro Chagas National Institute of Infectious Diseases-Fiocruz, Rio de Janeiro, Brazil.
11: Investigaciones Médicas en Salud, Lima, Peru.
12: Gladstone Institute of Virology and San Francisco AIDS Foundation, California.

Associated clinical trials:

Emtricitabine/Tenofovir Disoproxil Fumarate for HIV Prevention in Men | NCT00458393

Articles cited by this

Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med (2010) 50.17

Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med (2012) 27.84

Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med (2012) 20.03

Preexposure prophylaxis for HIV infection among African women. N Engl J Med (2012) 15.28

Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet (2013) 13.72

Tenofovir-based preexposure prophylaxis for HIV infection among African women. N Engl J Med (2015) 9.20

Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study. Lancet Infect Dis (2014) 5.59

Self-reported symptoms and medication side effects influence adherence to highly active antiretroviral therapy in persons with HIV infection. J Acquir Immune Defic Syndr (2001) 3.83

Tenofovir DF plus lamivudine or emtricitabine for nonoccupational postexposure prophylaxis (NPEP) in a Boston Community Health Center. J Acquir Immune Defic Syndr (2008) 3.10

Changes in glomerular kidney function among HIV-1-uninfected men and women receiving emtricitabine-tenofovir disoproxil fumarate preexposure prophylaxis: a randomized clinical trial. JAMA Intern Med (2015) 2.35

Tenofovir, emtricitabine, and tenofovir diphosphate in dried blood spots for determining recent and cumulative drug exposure. AIDS Res Hum Retroviruses (2012) 1.89

Bone mineral density in HIV-negative men participating in a tenofovir pre-exposure prophylaxis randomized clinical trial in San Francisco. PLoS One (2011) 1.84

Effects of Emtricitabine/Tenofovir on Bone Mineral Density in HIV-Negative Persons in a Randomized, Double-Blind, Placebo-Controlled Trial. Clin Infect Dis (2015) 1.76

The acceptability and feasibility of an HIV preexposure prophylaxis (PrEP) trial with young men who have sex with men. J Acquir Immune Defic Syndr (2013) 1.63

Randomized trial of clinical safety of daily oral tenofovir disoproxil fumarate among HIV-uninfected men who have sex with men in the United States. J Acquir Immune Defic Syndr (2013) 1.57

Changes in renal function associated with oral emtricitabine/tenofovir disoproxil fumarate use for HIV pre-exposure prophylaxis. AIDS (2014) 1.34

Inference about population attributable risk from cross-sectional studies. Am J Epidemiol (1979) 1.33

Bone mineral density changes among HIV-uninfected young adults in a randomised trial of pre-exposure prophylaxis with tenofovir-emtricitabine or placebo in Botswana. PLoS One (2014) 1.12

Renal function of participants in the Bangkok tenofovir study--Thailand, 2005-2012. Clin Infect Dis (2014) 0.99